Case Report of Cellgram® Autologous Mesenchymal Stem Cell Treatment for Relapsing-Remitting Multiple Sclerosis

Abstract

Multiple sclerosis is an autoimmune disease of the central nervous system that is increasing worldwide but difficult to diagnose and treat. Previous studies have revealed that the autologous Mesenchymal Stem Cells (MSC) for MS may serve as a possible effective tool for cell-based therapy of inflammatory, immune-mediated, and degenerative diseases due to their immunomodulatory, immunosuppressive, and regenerative potentials. This case report presents a patient diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) who was treated with an autologous mesenchymal stem cell drug (Cellgram®). We administered two doses of Cellgram® to a 54-year-old Southwest Asian male with a 28-year history of RRMS. Changes were also observed in manual muscle strength test, range of motion, and lower extremity stiffness, but the biggest change was in functional performance. Before treatment, the patient was unable to stand without assistance even with an orthosis, but was able to stand up from a wheelchair using a walker on the 24th day after the first injection, and was able to stand up from the wheelchair without assistance on the 26th day. Thirty days after the first injection, and 3 days after the second injection, he was able to walk a few steps back and forth using a walker. Five months after the first injection, he was able to climb six steps. In conclusion, this case report illustrates that MSC therapy might serve as a potential therapeutic option for RRMS as it may be a safe and effective treatment for MS patients.